Menu
J Clin Aesthet Dermatol. 2020;13(10) by Neal Bhatia, MD; Leon H. Kircik MD; Ava Shamban, MD; Varsha Bhatt, PhD; Radhakrishnan Pillai, PhD; and Eric Guenin, PharmD, PhD, MPH Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Kircik is with Indiana University School of Medicine in Indianapolis, IN, Physicians Skin Care, PLLC,
by Sharleen St. Surin-Lord, MD; Todd E. Schlesinger, MD, FAAD; and Eric Guenin, PharmD, PhD, MPH Dr. St. Surin-Lord is with Visage Dermatology and Aesthetics Center in Largo, Maryland. Dr. Schlesinger is with the Clinical Research Center of the Carolinas in Charleston, South Carolina. Dr. Guenin is with Ortho Dermatologics in Bridgewater, New Jersey. FUNDING: Ortho
Nicholas Schmidt, PhD; Eugene H. Gans, PhD Nicholas Schmidt, PhD; Eugene H. Gans, PhD are from Medicis Pharmaceutical Corporation, Scottsdale, Arizona
James Q. Del Rosso, DO, Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada; Radhakrishnan Pillai, PhD, Associate Director Project Management, Dow Pharmaceutical Sciences Inc., Petaluma, California; Robert Moore, PhD, Associate Principal Scientist, Dow Pharmaceutical Sciences Inc., Petaluma, California Disclosure: Dr. Del Rosso is a consultant, speaker, and researcher for Coria/Valeant, Allergan, Galderma, Graceway,
James Q. Del Rosso, DO, FAOCD, Valley Hospital Medical Center, Las Vegas, Nevada Abstract Acne vulgaris is the most common disorder encountered in ambulatory clinical practice comprising 11.3 percent of office visits to dermatologists in 2005.[1] By comparison, eczematous dermatoses, psoriasis, and skin cancer accounted for 6.2, 3.5, and 10 percent of office visits, respectively.[1]
